Diclofenac diethylamine — Competitive Intelligence Brief

Diclofenac diethylamine (Diclofenac diethylamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Pain Management, Rheumatology, Inflammation.

phase 3 Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2) Pain Management, Rheumatology, Inflammation Small molecule

Target snapshot

Diclofenac diethylamine (Diclofenac diethylamine) — Taisho Pharmaceutical Co., Ltd.. Diclofenac diethylamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Diclofenac diethylamine TARGET	Diclofenac diethylamine	Taisho Pharmaceutical Co., Ltd.	phase 3	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2)
Conventional strategy Aspirin	Conventional strategy Aspirin	Assistance Publique - Hôpitaux de Paris	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Prolensa 0.07% Ophthalmic Solution	Prolensa 0.07% Ophthalmic Solution	Nicole Fram M.D.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Loxoprofen sodium tablet	Loxoprofen sodium tablet	Sun Yat-sen University	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
Bromfenac Ophthalmic Solution B	Bromfenac Ophthalmic Solution B	Bausch & Lomb Incorporated	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Intravenous ibuprofen	Intravenous ibuprofen	Biomendi S.A.U.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Aspirin treatment	Aspirin treatment	VA Office of Research and Development	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class